Search Results 201-210 of 28507 for liver disease
The purpose of this study is to assess the combined impact of post-processing methods that quantify potential biomarkers of chronic liver disease (AEF, fECS) ...
The purpose of this study is to evaluate safety and effectiveness of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
A rapid loss of liver function can happen in people who don't even have liver disease. Find out about symptoms, treatment and prevention of this serious ...
... liver disease. Current efforts include studies of the incidence and causes of liver disease, the development of novel diagnostic tools, and clinical trials ...
... cirrhosis of the liver. Mayo researchers were among the first to identify nonalcoholic fatty liver disease and primary sclerosing cholangitis. Mayo ...
The Genetics, Epigenetics and Metabolomics Core at Mayo Clinic runs the Cystic Kidney and Liver Disease Biobank for patient tissue samples.
The Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index (ANI) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.